Étiquette : interaction CBD/THC

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder, Emily M. LaFrance et al, 2020,

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132   A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan Neuropsychopharmacology Reviews, 2018, 43, 142–154. doi : 10.1038/npp.2017.209; The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are 4550 chemical compounds and 4100 phytocannabinoids [...]

Lire la suite

Immune Responses Regulated by Cannabidiol, James M. Nichols and Barbara L.F. Kaplan, 2019

Immune Responses Regulated by Cannabidiol James M. Nichols and Barbara L.F. Kaplan Cannabis and Cannabinoid Research, 2019, Volume X, Number X Doi : 10.1089/can.2018.0073   Abstract Introduction : Cannabidiol (CBD) as Epidiolex (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and [...]

Lire la suite

Bibliographie : Interactions et antagonisme THC – CBD, Docteur Christian SUEUR, GRECC, mars 2020.

Bibliographie : Interactions et antagonisme THC - CBD   Docteur Christian SUEUR, GRECC, mars 2020.   Les interactions entre le THC et le CBD sur le système endocannabinoide, quant aux effets psychotomimetic (production de "symptomes psychotiques") sont opposés : là où le THC produit préférentiellement de l'anxiété, et des effets "psychotisants", le CBD est plutôt anxiolytique et "antipsychotique". Ces deux phytocannabinoïdes sont "antagonistes", et contribuent, parmi d'autres inter-relations entre les phytocannabinoïdes, les terpènes et les flavonoïdes composant le cannabis, aux "effets d'entourage" fondamentaux, tout autant quant à la production "d'effets indésirables" et de risques pour la santé mentale du consommateur, que dans le cadre de [...]

Lire la suite

The effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species, Faith Borgan et al., 2019

The effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species Faith Borgan, Katherine Beck, Emma Butler, Robert McCutcheon, Mattia Veronese, Anthony Vernon, Oliver D. Howes Psychopharmacology, 2019 Doi : 10.1007/s00213-019-05283-3   Abstract Rationale : While cannabis-based medicinal products have been shown to be effective for numerous neurological and psychiatric disorders, the evidence base regarding their adverse cognitive effects is poorly understood. The cannabinoid 1 receptor modulates memory performance via intracellular and extracellular mechanisms that alter synaptic transmission and plasticity. While previous literature has consistently shown that chronic cannabis users exhibitmarked cognitive impairments,mixed findings have been reported in the context [...]

Lire la suite

Species-specific susceptibility to cannabisinduced convulsions, Benjamin J Whalley et al., 2018

Species-specific susceptibility to cannabis-induced convulsions Benjamin J Whalley, Hong Lin, Lynne Bell, Thomas Hill, Amesha Patel, Roy A Gray, C Elizabeth Roberts, Orrin Devinsky, Michael Bazelot, Claire M Williams and Gary J Stephens British Journal of Pharmacology, 2018, 1-18. Doi : 10.1111/bph.14165   BACKGROUND AND PURPOSE Numerous claims are made for cannabis’ therapeutic utility upon human seizures, but concerns persist about risks. A potential confounder is the presence of both Δ9-tetrahydrocannabinol (THC), variously reported to be pro- and anticonvulsant, and cannabidiol (CBD), widely confirmed as anticonvulsant. Therefore, we investigated effects of prolonged exposure to different THC/CBD cannabis extracts on seizure activity and associated measures of endocannabinoid [...]

Lire la suite

Cannabinoids in Pain Management and Palliative Medicine, Winfried Häuser et al., 2017

Cannabinoids in Pain Management and Palliative Medicine An Overview of Systematic Reviews and Prospective Observational Studies Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke The Deutsches Ärzteblatt International,  2017, 114, 627–634. Doi : 10.3238/arztebl.2017.0627   SUMMARY Background : There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. Methods : We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane [...]

Lire la suite

A behavioural comparison of acute and chronic D9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice, Leonora E. Long et al., 2010

A behavioural comparison of acute and chronic D9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice Leonora E. Long, Rose Chesworth, Xu-Feng Huang, Iain S. McGregor, Jonathon C. Arnold and Tim Karl International Journal of Neuropsychopharmacology, 2010, 13, 861–876. doi : 10.1017/S1461145709990605   Abstract Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the psychotropic cannabis constituent D9 tetrahydro-cannabinol (D9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia. Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, [...]

Lire la suite

Drug-drug interactions as a result of coadministering Δ9-THC and CBD with other psychotropic agents, Carola Rong et al., 2018

Drug-drug interactions as a result of coadministering Δ9-THC and CBD with other psychotropic agents Carola Rong, Nicole E. Carmona, Yena L. Lee, Renee-Marie Ragguett, Zihang Pan, Joshua D. Rosenblat, Mehala Subramaniapillai, Margarita Shekotikhina, Fahad Almatham, Asem Alageel, Rodrigo Mansur, Roger C. Ho & Roger S. McIntyre Expert Opinion on Drug Safety, 2018, 17:1, 51-54. Doi : 10.1080/14740338.2017.1397128   ABSTRACT Introduction : To determine, via narrative, non-systematic review of pre-clinical and clinical studies, whether the effect of cannabis on hepatic biotransformation pathways would be predicted to result in clinically significant drug-drug interactions (DDIs) with commonly prescribed psychotropic agents. Areas covered: A non-systematic literature search was conducted using the following [...]

Lire la suite

Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use, Paulo Fleury-Teixeira et al., 2019

Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, October 2019, Volume 10, Article 1145 doi : 10.3389/fneur.2019.01145   Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]

Lire la suite